View Older Stories View More Recent Stories

Mar 1, 2026 06:49PM WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Ca
Feb 26, 2026 08:08AM Eisai and Advocacy Leaders Launch "Kompass," a Digital Destination to Help Patients and Caregivers Navigate the Complexities of Kidney Cancer
Nov 3, 2025 08:08AM Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
Oct 2, 2025 08:08AM Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
May 20, 2025 08:08AM Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
Nov 26, 2024 12:50AM Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Sep 16, 2024 08:08PM LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients
Sep 4, 2024 08:08AM Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024, Including First Interim Analysis Results from the Phase 3 LEAP-012 Trial
Jun 27, 2024 04:35PM New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA® (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of Adult Patie
Jun 27, 2024 09:35AM New Post-Hoc Analysis from Phase 3 REFLECT Trial Presented at ESMO GI 2024 Explores Efficacy Outcomes with LENVIMA® (lenvatinib) Based on Depth of Tumor Response in Unresectable Hepatocellular Carcin
May 23, 2024 08:08AM Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Jan 18, 2024 08:08AM Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024
Jan 16, 2024 08:08AM Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024
Oct 11, 2023 08:08AM Eisai to Present Research From Oncology Portfolio and Pipeline at ESMO Congress 2023
Sep 25, 2023 01:17AM "LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Aug 17, 2023 08:00AM EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS
Jul 19, 2023 09:23PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 19, 2023 07:30PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 6, 2023 08:00PM FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 11, 2023 08:13PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 9, 2023 06:45PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 7, 2023 11:32PM Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
May 23, 2023 08:08AM Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 19, 2023 08:20PM Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 15, 2023 07:27PM Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
Apr 11, 2023 08:08AM EISAI AND PATIENT ADVOCACY PARTNERS LAUNCH MADE OF MORE -- AN EDUCATION INITIATIVE TO SPOTLIGHT HEAD AND NECK CANCER
Mar 31, 2023 12:55AM Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Mar 30, 2023 07:31PM ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
Mar 30, 2023 07:30PM EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Mar 23, 2023 08:08AM Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 5, 2023 06:30PM FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Feb 27, 2023 06:30PM BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jan 29, 2023 06:30PM LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
Jan 26, 2023 06:30PM MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
Jan 18, 2023 08:08AM Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
Jan 15, 2023 07:30PM EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN
Jan 10, 2023 06:30PM EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Jan 6, 2023 11:30PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 6, 2023 02:31PM Eisai, Biogen (BIIB) Confirm FDA Approval of LEQEMBI Under Accelerated Approval Pathway for Treatment of Alzheimer's Disease
Jan 6, 2023 02:30PM FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Dec 22, 2022 06:45PM EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
Dec 22, 2022 03:07AM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 1, 2022 08:08AM Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Nov 29, 2022 07:50PM ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND
Nov 29, 2022 07:50PM EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Nov 23, 2022 06:30PM EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
Oct 21, 2022 10:30AM Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Sep 28, 2022 07:00AM Eisai, Biogen (BIIB) Announce Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint for Reduction of Early Alzheimer's Disease
Sep 27, 2022 07:30PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E
View More Recent Stories View Older Stories